Business description
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
Management board & Supervisory board
| CEO |
| Dr. Thomas Schinecker |
| Management board |
| Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Barbara Schädler, Boris L. Zaïtra |
| Supervisory board |
| Dr. Severin Schwan, André Hoffmann, Anita Hauser, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Jörg Duschmalé |
Company data
| Name: |
Roche Holding |
| Address: |
Grenzacherstraße 124,CH-4070 Basel |
| Phone: |
+41-61-688-1111 |
| Fax: |
- |
| E-mail: |
basel.webmaster@roche.com
|
| Internet: |
www.roche.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
88.00% |
| IPO date: |
03/04/1995 |
Investor relations
| Name: |
Bruno Eschli |
| IR phone: |
+41 (61) 687 5284 |
| IR Fax: |
+41 (61) 691 0014 |
| IR e-mail: |
bruno.eschli@roche.com
|
